Table 3.

Comparison between patients who achieved disease control and those who did not achieve disease control

	Achieved disease control (n=8)	Did not achieve disease control (n=32)	P value
Men:women	1:7	5:27	0.9
Age at disease diagnosis, median (IQR), years	14.2 (11.3–15.2)	14.3 (11.3–16.5)	0.9
Age at first RTX use, median (IQR), years	17.5 (15.4–19.9)	21.2 (17.1–28.3)	0.06
Interval of first RTX after diagnosis, median (IQR), years	2.1 (0.2–8.5)	7.8 (2.9–13.1)	0.02*
Number of times of RTX administrations, mean (SD)	2.9 (2)	3.4 (2)	0.6
SLEDAI-2K before RTX, median (IQR)	8 (5–20)	8 (6–12)	0.6
SLEDIA-2K 2 years after RTX, median (IQR)	2 (1–2)	6 (4–8)	<0.01*
Year of diagnosis, median (IQR)	2012 (2007–2018)	2015 (2006–2019)	0.8
Duration of follow-up, median (IQR), years	2.2 (1.2–4.4)	2.9 (2.5–4.5)	0.6

*p<0.05.

RTX, rituximab; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.